Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Authors

Anita Kohli
Anuoluwapo Osinusi
Zayani Sims
Amy Nelson
Eric G Meissner
Lisa L Barrett
Kerry Townsend, George Washington University
+ several additional authors

Document Type

Journal Article

Publication Date

3-21-2015

Journal

Lancet

Volume

385

Issue

9973

Inclusive Pages

1107-13

DOI

10.1016/S0140-6736(14)61228-9

Keywords

Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; RNA, Viral; Ribavirin; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load

APA Citation

Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E., Barrett, L., Townsend, K., & + several additional authors (2015). Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.. Lancet, 385 (9973). http://dx.doi.org/10.1016/S0140-6736(14)61228-9

Peer Reviewed

1